Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Oki

Showing results (81-90 of 164) with videos related to

Pageof 17
Sort By:
British Journal of Haematology|January 7, 2014
The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphomaYasuhiro Oki, Hubert Chuang, Beth Chasen, et al.
Leukemia & Lymphoma|September 20, 2019
<i>De novo</i> CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab eraBei Hu, Loretta J Nastoupil, Sanam Loghavi, et al.
Blood|January 10, 2015
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expressionEric D Jacobsen, Jeff P Sharman, Yasuhiro Oki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2009
DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromesLanlan Shen, Hagop Kantarjian, Yi Guo, et al.
Haematologica|September 8, 2018
ABVD plus rituximab <i>versus</i> ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 studyPaolo Strati, Michelle A Fanale, Yasuhiro Oki, et al.
Cancer|December 17, 2016
A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantationSarah A Milgrom, Shekeab Jauhari, John P Plastaras, et al.
International Journal of Radiation Oncology, Biology, Physics|April 12, 2014
Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiationBouthaina S Dabaja, Kenneth Hess, Ferial Shihadeh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2013
Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphomaYasuhiro Oki, Daniela Buglio, Michelle Fanale, et al.
The Lancet. Oncology|July 22, 2014
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b studyAnas Younes, Catherine Thieblemont, Franck Morschhauser, et al.
Blood|December 2, 2017
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignanciesIan W Flinn, Susan O'Brien, Brad Kahl, et al.
Pageof 17

Showing results (81-90 of 164) with videos related to

Sort By:
Pageof 17
British Journal of Haematology|January 7, 2014
The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphomaYasuhiro Oki, Hubert Chuang, Beth Chasen, et al.
Leukemia & Lymphoma|September 20, 2019
<i>De novo</i> CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab eraBei Hu, Loretta J Nastoupil, Sanam Loghavi, et al.
Blood|January 10, 2015
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expressionEric D Jacobsen, Jeff P Sharman, Yasuhiro Oki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2009
DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromesLanlan Shen, Hagop Kantarjian, Yi Guo, et al.
Haematologica|September 8, 2018
ABVD plus rituximab <i>versus</i> ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 studyPaolo Strati, Michelle A Fanale, Yasuhiro Oki, et al.
Cancer|December 17, 2016
A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantationSarah A Milgrom, Shekeab Jauhari, John P Plastaras, et al.
International Journal of Radiation Oncology, Biology, Physics|April 12, 2014
Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiationBouthaina S Dabaja, Kenneth Hess, Ferial Shihadeh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2013
Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphomaYasuhiro Oki, Daniela Buglio, Michelle Fanale, et al.
The Lancet. Oncology|July 22, 2014
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b studyAnas Younes, Catherine Thieblemont, Franck Morschhauser, et al.
Blood|December 2, 2017
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignanciesIan W Flinn, Susan O'Brien, Brad Kahl, et al.
Pageof 17